CXCL4/PF4 recombinant protein: A key mediator in myelofibrosis inflammation regulation and hematopoietic-stromal cross-talk

Author: Senior Product Manager of UA Views：9

This article focuses on the molecular characteristics and biological functions of the chemokine CXCL4/platelet factor 4, systematically elucidating its central role as an inflammatory regulator and fibrosis driver in primary myelofibrosis. It analyzes the molecular mechanisms by which CXCL4 promotes bone marrow fibrosis through hematopoietic-stromal cross-talk and explores the therapeutic potential of targeting CXCL4 to alleviate inflammation in myelofibrosis.

Recent Advances
Product Information

Recent Advances

CXCL4/PF4 Recombinant Protein: A Key Mediator in Inflammatory Regulation and Hematopoietic-Stromal Crosstalk in Myelofibrosis

Overview: This article systematically elucidates the molecular characteristics and biological functions of the chemokine CXCL4/platelet factor 4, focusing on its central role as an inflammatory modulator and fibrosis driver in primary myelofibrosis. It analyzes the molecular mechanisms by which CXCL4 promotes myelofibrosis through hematopoietic-stromal crosstalk and explores the therapeutic potential of targeting CXCL4 to alleviate inflammation in myelofibrosis.

1. Disease Characteristics and Pathogenesis of Primary Myelofibrosis

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that leads to progressive bone marrow fibrosis. Although cellular mutations involved in PMF pathogenesis have been extensively studied, the sequential events driving stromal activation and fibrosis through hematopoietic-stromal crosstalk remain unclear. This knowledge gap has hindered the development of strategies to target the bone marrow fibrotic microenvironment. Recent studies using unbiased approaches and validation in MPN patients have identified the spatially differential expression of the chemokine CXCL4/platelet factor 4 as a marker of fibrosis progression. This discovery provides new insights into understanding the causal relationship between inflammation and stromal activation in myelofibrosis.

2. Molecular Characteristics and Expression Distribution of CXCL4

CXCL4, also known as platelet factor 4, is a member of the C-X-C chemokine family and was the first chemokine to be identified. The human PF4 gene encodes a mature protein of approximately 7.8 kDa, consisting of 70 amino acids. CXCL4 is primarily localized in the α-granules of platelets, with about 20 μg of PF4 per 1×10⁹ platelets, indicating an extremely high concentration. In plasma, PF4 concentrations range from 2 to 10 ng/mL. This distribution pattern—highly enriched in platelets but maintained at low levels in plasma—enables rapid release and local regulatory effects upon platelet activation. In the bone marrow microenvironment, CXCL4 can be released by megakaryocytes and platelets, participating in signaling crosstalk between hematopoietic cells and stromal cells.

3. Pro-Fibrotic Effects of CXCL4 in Myelofibrosis

Studies have shown that high expression of CXCL4 in MPN has pro-fibrotic effects and serves as a modulator of characteristic inflammation. Deficiency of CXCL4 in hematopoietic cells improves MPN phenotypes, reduces stromal cell activation and bone marrow fibrosis, and mitigates multiple pathological features in three PMF mouse models: first, activation of megakaryocyte pro-fibrotic pathways; second, inflammation driven by fibrogenic cells; and third, JAK/STAT activation in megakaryocytes and stromal cells. These findings establish the central role of CXCL4 in the pathogenesis of myelofibrosis, indicating that it is not merely a marker of inflammation but a functional mediator driving fibrosis progression. Therefore, targeting CXCL4 may represent an effective approach to alleviating inflammation in PMF.

4. Pleiotropic Biological Functions of CXCL4

CXCL4 exhibits pleiotropic biological functions. It is recognized as a potent anti-angiogenic chemokine, capable of inhibiting endothelial cell proliferation and migration, thereby suppressing angiogenesis. The angiostatic activity of CXCL4 involves multiple mechanisms, including interference with angiogenic growth factors such as bFGF-2 and VEGF165, activation of the CXCR3B receptor, interactions with integrins, and disruption of cell cycle progression. In the bone marrow microenvironment, these functions of CXCL4 may participate in regulating vascular homeostasis and hematopoietic cell localization. Additionally, CXCL4 can modulate immune cell functions and regulate inflammatory responses, aligning with its role as an inflammatory modulator in myelofibrosis.

5. Conclusion

In CXCL4-related basic research and drug development, high-quality recombinant CXCL4 protein is a critical tool for elucidating its pro-fibrotic mechanisms and evaluating targeted intervention strategies. To meet this research demand, Uni offers CXCL4/PF4 Protein, Human. This product is suitable for studying the pro-fibrotic mechanisms of CXCL4 in myelofibrosis, analyzing interactions between CXCL4 and stromal cells/megakaryocytes, and evaluating therapeutic strategies targeting CXCL4.

As the first identified chemokine, CXCL4/platelet factor 4, with its high enrichment in platelets, pro-fibrotic effects in the bone marrow microenvironment, and central role in MPN inflammation regulation, has emerged as a key target in myelofibrosis pathogenesis research and therapeutic intervention. Its pivotal role in hematopoietic-stromal crosstalk provides a new framework for understanding the sequential events in myelofibrosis. CXCL4/PF4 Protein, Human offers reliable support for CXCL4-related mechanistic studies and targeted strategy development, driving further exploration in the field of myelofibrosis treatment.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next